| Symbol | PTCT |
|---|---|
| Name | PTC THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 500 WARREN CORPORATE CENTER DRIVE, WARREN, New Jersey, 07059, United States |
| Telephone | +1 908 - 222-7000 |
| Fax | — |
| — | |
| Website | https://www.ptcbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001070081 |
| Description | PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology. Additional info from NASDAQ: |
📋 Almstead Neil Gregory (Officer) plans to sell 25K shares of PTC THERAPEUTICS, INC. (at $88.88 each, total $2.2M) Filed: Jul 07, 2026 | ID: 005150
Read more📋 Almstead Neil Gregory (Officer) plans to sell 22K shares of PTC THERAPEUTICS, INC. (at $86.00 each, total $1.9M) Filed: Jul 06, 2026 | ID: 005117
Read more📋 Boulding Mark Elliott (Officer) plans to sell 5K shares of PTC THERAPEUTICS, INC. (at $84.14 each, total $427K) Filed: Jul 06, 2026 | ID: 005114
Read moreAlmstead Neil Gregory 🟡 adjusted position in 8.1K shares (2 derivative) of PTC THERAPEUTICS, INC. (PTCT) at $85.26 ($1.3M) Transaction Date: Jun 26, 2026 | Filing ID: 000019
Read moreAlmstead Neil Gregory 🟡 adjusted position in 26.3K shares (5 derivative) of PTC THERAPEUTICS, INC. (PTCT) at $87.00 ($4.3M) Transaction Date: Jun 24, 2026 | Filing ID: 000017
Read more📋 Almstead Neil Gregory (Officer) plans to sell 8K shares of PTC THERAPEUTICS, INC. (at $85.26 each, total $693K) Filed: Jun 26, 2026 | ID: 004919
Read more📋 Almstead Neil Gregory (Officer) plans to sell 21K shares of PTC THERAPEUTICS, INC. (at $85.97 each, total $1.8M) Filed: Jun 25, 2026 | ID: 004899
Read moreAlmstead Neil Gregory 🟡 adjusted position in 23.7K shares (1 derivative) of PTC THERAPEUTICS, INC. (PTCT) at $81.21 ($3.1M) Transaction Date: Jun 22, 2026 | Filing ID: 000014
Read more📋 Almstead Neil Gregory (Officer) plans to sell 5K shares of PTC THERAPEUTICS, INC. (at $85.03 each, total $453K) Filed: Jun 24, 2026 | ID: 004862
Read moreUtter Christine Marie 🟡 adjusted position in 19.7K shares (1 derivative) of PTC THERAPEUTICS, INC. (PTCT) at $75.56 ($2.5M) Transaction Date: Jun 17, 2026 | Filing ID: 000010
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT01370447 | EPI-743 for Mitochondrial Respiratory Chain Diseases | — | Mitochondrial Diseases | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07159139 | Vatiquinone Expanded Access Protocol | — | Mitochondrial Disease | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT02592941 | Deflazacort Expanded Access Program for Children, Adolescents and Adults With D… | — | Duchenne Muscular Dystrophy | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT07681713 | Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxi… | Phase3 | Friedreich's Ataxia | Not_Yet_Recruiting | 2026-08-15 | 2029-03-15 | ClinicalTrials.gov |
| NCT07614126 | Study of L-dopa Treatment in Patients With a Neurodevelopmental Disorder (CTNNB… | Na | CTNNB1 | Recruiting | 2026-04-08 | 2027-05-01 | ClinicalTrials.gov |
| NCT06302348 | A Study of Sepiapterin in Participants With Phenylketonuria (PKU) | Phase3 | Phenylketonuria | Recruiting | 2024-03-04 | 2031-02-28 | ClinicalTrials.gov |
| NCT05515536 | A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With F… | Phase3 | Friedreich Ataxia | Active_Not_Recruiting | 2022-12-08 | 2027-12-31 | ClinicalTrials.gov |
| NCT05485987 | A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia | Phase2 | Friedreich Ataxia | Completed | 2022-10-12 | 2024-08-29 | ClinicalTrials.gov |
| NCT05218655 | A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With In… | Phase3 | Inherited Mitochondrial Disease | Completed | 2022-06-22 | 2025-04-15 | ClinicalTrials.gov |
| NCT05269355 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) | Phase2 | Leiomyosarcoma | Terminated | 2022-05-23 | 2024-07-17 | ClinicalTrials.gov |
| NCT05349721 | Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophi… | Phase2 | Amyotrophic Lateral Sclerosis | Terminated | 2022-05-15 | 2025-01-30 | ClinicalTrials.gov |
| NCT05166161 | A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria | Phase3 | Phenylketonuria | Active_Not_Recruiting | 2022-02-14 | 2026-06-30 | ClinicalTrials.gov |
| NCT04336826 | A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants… | Phase2 | Nonsene Mutation Duchenne Muscular Dystrophy | Completed | 2021-12-29 | 2023-08-07 | ClinicalTrials.gov |
| NCT05099640 | A Study of PTC923 in Participants With Phenylketonuria | Phase3 | Phenylketonuria | Completed | 2021-09-30 | 2023-05-03 | ClinicalTrials.gov |
| NCT04903288 | A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for… | Phase2 | AADC Deficiency | Active_Not_Recruiting | 2021-05-12 | 2028-04-30 | ClinicalTrials.gov |
| NCT04577352 | A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of P… | Phase2 | Friedreich Ataxia | Completed | 2020-12-17 | 2023-10-02 | ClinicalTrials.gov |
| NCT04378075 | A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondri… | Phase2 | Mitochondrial Diseases | Terminated | 2020-09-28 | 2023-12-27 | ClinicalTrials.gov |
| NCT04439071 | A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized… | Phase2 | Pneumonia | Terminated | 2020-07-09 | 2022-07-20 | ClinicalTrials.gov |
| NCT03783923 | A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dys… | Phase3 | Limb-Girdle Muscular Dystrophy | Terminated | 2019-10-31 | 2021-01-01 | ClinicalTrials.gov |
| NCT04014530 | Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorecta… | Phase1 | Colorectal Cancer | Recruiting | 2019-08-01 | 2023-08-01 | ClinicalTrials.gov |
| NCT03796637 | A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duch… | Phase2 | Duchenne Muscular Dystrophy | Completed | 2019-04-11 | 2019-06-03 | ClinicalTrials.gov |
| NCT03761095 | A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants W… | Phase1 | Leiomyosarcoma | Completed | 2019-03-13 | 2024-02-05 | ClinicalTrials.gov |
| NCT03712124 | A Study of CNSA-001 in Women With Diabetic Gastroparesis | Phase2 | Gastroparesis | Completed | 2019-02-27 | 2019-10-08 | ClinicalTrials.gov |
| NCT03519711 | A Study of PTC923 (CNSA-001) in Primary Tetrahydrobiopterin (BH4) Deficient Par… | Phase1 | BH4 Deficiency | Completed | 2019-01-03 | 2020-10-02 | ClinicalTrials.gov |
| NCT04117880 | A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Ani… | Phase2 | Aniridia | Withdrawn | 2018-12-31 | 2021-01-31 | ClinicalTrials.gov |
| NCT03648827 | A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duch… | Phase2 | Duchenne Muscular Dystrophy | Completed | 2018-12-21 | 2020-10-23 | ClinicalTrials.gov |
| NCT03642145 | A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystro… | Phase3 | Duchenne Muscular Dystrophy | Withdrawn | 2018-10-31 | 2021-07-31 | ClinicalTrials.gov |
| NCT03761069 | Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias | Phase1 | Leukemia, Myeloid, Acute | Terminated | 2018-10-29 | 2021-12-28 | ClinicalTrials.gov |
| NCT03605550 | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic P… | Phase1 | High Grade Glioma | Active_Not_Recruiting | 2018-08-01 | 2029-03-01 | ClinicalTrials.gov |
| NCT03206645 | Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy | Phase1 | Ovarian Cancer | Completed | 2017-08-28 | 2024-03-31 | ClinicalTrials.gov |
| NCT03179631 | Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy | Phase3 | Muscular Dystrophy, Duchenne | Completed | 2017-07-06 | 2023-07-25 | ClinicalTrials.gov |
| NCT02926066 | A Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) De… | Phase2 | Aromatic Amino Acid Decarboxylase Deficiency | Completed | 2016-11-09 | 2022-05-16 | ClinicalTrials.gov |
| NCT02758626 | Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome | Phase2 | Epilepsy | Completed | 2016-11-01 | 2021-02-27 | ClinicalTrials.gov |
| NCT02819557 | Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular… | Phase2 | Duchenne Muscular Dystrophy | Completed | 2016-06-09 | 2018-02-09 | ClinicalTrials.gov |
| NCT02647359 | Study of Ataluren in Participants With Nonsense Mutation Aniridia | Phase2 | Aniridia | Completed | 2016-01-31 | 2021-01-22 | ClinicalTrials.gov |
| NCT02460679 | Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral … | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2016-01-14 | 2018-02-23 | ClinicalTrials.gov |
| NCT02404480 | PTC596 in Patients With Advanced Solid Tumors | Phase1 | Cancer | Completed | 2016-01-01 | 2017-02-06 | ClinicalTrials.gov |
| NCT02456103 | Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibro… | Phase3 | Cystic Fibrosis | Terminated | 2015-08-31 | 2017-06-02 | ClinicalTrials.gov |
| NCT02485431 | Food Effect and Bioavailability of Deflazacort Formulations in Healthy Voluntee… | Phase1 | Healthy Volunteers | Completed | 2015-06-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02369731 | Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystro… | — | Muscular Dystrophy, Duchenne | Completed | 2015-04-30 | 2025-03-31 | ClinicalTrials.gov |
| NCT02409004 | Effects of Rifampin on the Pharmacokinetics of Ataluren | Phase1 | Healthy | Completed | 2015-02-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02251600 | A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects… | Phase1 | Duchenne Muscular Dystrophy | Completed | 2014-12-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02295748 | An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerabilit… | Phase1 | Duchenne Muscular Dystrophy | Completed | 2014-12-01 | 2017-08-24 | ClinicalTrials.gov |
| NCT02286622 | A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Phar… | Phase1 | Renal Impairment | Completed | 2014-12-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02286609 | A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Defla… | Phase1 | Hepatic Impairment | Completed | 2014-12-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT02286635 | Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single… | Phase1 | Healthy Volunteers | Completed | 2014-11-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01395641 | A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylas… | Phase1 | Aromatic L-amino Acid Decarboxylase (AADC) Deficiency | Completed | 2014-10-22 | 2022-03-07 | ClinicalTrials.gov |
| NCT02139306 | Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF) | Phase3 | Cystic Fibrosis | Completed | 2014-08-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02107859 | Study of Ataluren (PTC124) in Cystic Fibrosis | Phase3 | Cystic Fibrosis | Terminated | 2014-05-23 | 2017-06-05 | ClinicalTrials.gov |
| NCT02090959 | An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation … | Phase3 | Muscular Dystrophy, Duchenne | Terminated | 2014-03-20 | 2018-06-12 | ClinicalTrials.gov |
| NCT02352896 | Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Synd… | Phase2 | Leigh Syndrome | Completed | 2014-01-31 | 2023-10-30 | ClinicalTrials.gov |
| NCT01910168 | A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for… | — | Muscular Atrophy, Spinal | Completed | 2013-08-01 | 2014-02-01 | ClinicalTrials.gov |
| NCT01826487 | Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscu… | Phase3 | Muscular Dystrophy, Duchenne | Completed | 2013-03-26 | 2015-08-20 | ClinicalTrials.gov |
| NCT01728064 | Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia | Phase2 | Friedreich's Ataxia | Completed | 2012-12-31 | 2016-02-29 | ClinicalTrials.gov |
| NCT01721733 | Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome | Phase2 | Leigh Syndrome | Completed | 2012-10-31 | 2015-05-31 | ClinicalTrials.gov |
| NCT01557400 | Study of Ataluren for Previously Treated Participants With Nonsense Mutation Du… | Phase3 | Duchenne Muscular Dystrophy | Completed | 2012-05-20 | 2018-01-19 | ClinicalTrials.gov |
| NCT01247207 | Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dys… | Phase3 | Duchenne Muscular Dystrophy | Completed | 2010-11-30 | 2026-02-10 | ClinicalTrials.gov |
| NCT01158300 | PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central … | Phase1 | Brain and Central Nervous System Tumors | Completed | 2010-11-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT01140451 | Extension Study of Ataluren (PTC124) in Cystic Fibrosis | Phase3 | Cystic Fibrosis | Completed | 2010-08-12 | 2013-12-02 | ClinicalTrials.gov |
| NCT01141075 | Ataluren for Nonsense Mutation Methylmalonic Acidemia | Phase2 | Amino Acid Metabolism, Inborn Errors | Terminated | 2010-07-19 | 2011-11-03 | ClinicalTrials.gov |
| NCT01009294 | Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation… | Phase2 | Duchenne Muscular Dystrophy | Terminated | 2010-01-13 | 2010-03-23 | ClinicalTrials.gov |
| NCT00947193 | Study of Ataluren (PTC124) in Hemophilia A and B | Phase2 | Hemophilia A | Terminated | 2009-10-14 | 2011-08-30 | ClinicalTrials.gov |
| NCT00803205 | Study of Ataluren (PTC124™) in Cystic Fibrosis | Phase3 | Cystic Fibrosis | Completed | 2009-09-08 | 2011-11-12 | ClinicalTrials.gov |
| NCT00911248 | PTC299 for Treatment of Neurofibromatosis Type 2 | Phase2 | Neurofibromatosis 2 | Terminated | 2009-07-31 | 2012-03-31 | ClinicalTrials.gov |
| NCT00847379 | Phase 2B Extension Study of Ataluren (PTC124) in Duchenne/Becker Muscular Dystr… | Phase2 | Duchenne Muscular Dystrophy | Terminated | 2009-01-31 | 2010-05-24 | ClinicalTrials.gov |
| NCT00686842 | PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma | Phase1 | Kaposi's Sarcoma | Terminated | 2008-09-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00759876 | Phase 2a Extension Study of Ataluren (PTC124) in Duchenne Muscular Dystrophy (D… | Phase2 | Duchenne Muscular Dystrophy | Terminated | 2008-08-13 | 2010-05-17 | ClinicalTrials.gov |
| NCT00704821 | PTC299 for Treatment of Advanced Cancer | Phase1 | Advanced Cancer | Terminated | 2008-07-03 | 2012-02-24 | ClinicalTrials.gov |
| NCT00592553 | Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/… | Phase2 | Duchenne Muscular Dystrophy | Completed | 2008-02-29 | 2009-12-31 | ClinicalTrials.gov |
| NCT00508586 | PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer | Phase1 | Metastatic Breast Cancer | Completed | 2007-11-01 | 2012-03-01 | ClinicalTrials.gov |
| NCT00458341 | A Study of Ataluren in Pediatric Participants With Cystic Fibrosis | Phase2 | Cystic Fibrosis | Completed | 2007-03-23 | 2008-02-29 | ClinicalTrials.gov |
| NCT00351078 | PTC124 for the Treatment of Cystic Fibrosis | Phase2 | Cystic Fibrosis | Completed | 2006-12-01 | 2007-07-01 | ClinicalTrials.gov |
| NCT00264888 | Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy | Phase2 | Duchenne Muscular Dystrophy | Completed | 2005-12-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00237380 | Safety and Efficacy of Ataluren (PTC124) for Cystic Fibrosis | Phase2 | Cystic Fibrosis | Completed | 2005-11-30 | 2006-05-31 | ClinicalTrials.gov |
| NCT00234663 | PTC124 for Cystic Fibrosis | Phase2 | Cystic Fibrosis | Completed | 2005-09-01 | 2006-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Vatiquinone | Other | Phase PHASE3 | Friedreich's Ataxia | NOT_YET_RECRUITING | NCT07681713 |
| PTC923 | Other | Phase PHASE3 | Phenylketonuria | ACTIVE_NOT_RECRUITING | NCT05166161 |
| Sepiapterin | Other | Phase PHASE3 | Phenylketonuria | RECRUITING | NCT06302348 |
| L-Dopa | Other | Approved | CTNNB1 | RECRUITING | NCT07614126 |